SG10201900598TA - Factor viii formulation - Google Patents

Factor viii formulation

Info

Publication number
SG10201900598TA
SG10201900598TA SG10201900598TA SG10201900598TA SG10201900598TA SG 10201900598T A SG10201900598T A SG 10201900598TA SG 10201900598T A SG10201900598T A SG 10201900598TA SG 10201900598T A SG10201900598T A SG 10201900598TA SG 10201900598T A SG10201900598T A SG 10201900598TA
Authority
SG
Singapore
Prior art keywords
factor viii
viii formulation
formulation
none
publication
Prior art date
Application number
SG10201900598TA
Inventor
Uwe Liebing
Hubert Metzner
Christina Bodenbender
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of SG10201900598TA publication Critical patent/SG10201900598TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FACTOR VIII FORMULATION The invention relates to factor VIII compositions and their use. Figure for publication: None
SG10201900598TA 2014-08-04 2015-07-24 Factor viii formulation SG10201900598TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14179732 2014-08-04

Publications (1)

Publication Number Publication Date
SG10201900598TA true SG10201900598TA (en) 2019-02-27

Family

ID=51298563

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900598TA SG10201900598TA (en) 2014-08-04 2015-07-24 Factor viii formulation
SG11201700550YA SG11201700550YA (en) 2014-08-04 2015-07-24 Factor viii formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201700550YA SG11201700550YA (en) 2014-08-04 2015-07-24 Factor viii formulation

Country Status (17)

Country Link
US (1) US10238718B2 (en)
EP (1) EP3177317B1 (en)
JP (1) JP6516829B2 (en)
KR (1) KR102192494B1 (en)
CN (1) CN106687126B (en)
AU (1) AU2015299224B2 (en)
BR (1) BR112017002090B1 (en)
CA (1) CA2956412A1 (en)
DK (1) DK3177317T3 (en)
ES (1) ES2788870T3 (en)
IL (1) IL250343B (en)
MX (1) MX2017000862A (en)
NZ (1) NZ729629A (en)
PL (1) PL3177317T3 (en)
RU (1) RU2689338C2 (en)
SG (2) SG10201900598TA (en)
WO (1) WO2016020210A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279437B (en) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
WO2018101358A1 (en) * 2016-11-29 2018-06-07 Ｓｐｉｂｅｒ株式会社 Protein composition, method for producing same and method for improving heat stability
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
CA3082043A1 (en) * 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
CN113105562B (en) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 Application of mutant single-chain human coagulation factor VIII in preparation of fusion protein
CN112138149A (en) * 2019-06-28 2020-12-29 北京基科晟斯医药科技有限公司 Recombinant factor VIII formulations
CN116322920A (en) 2020-11-09 2023-06-23 武田药品工业株式会社 Purification of FVIII from plasma using silica adsorption

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
ES2097120T3 (en) 1989-07-24 1997-04-01 Bayer Ag STABILIZATION OF HIGHLY PURIFIED PROTEINS.
DE4001451A1 (en) 1990-01-19 1991-08-01 Octapharma Ag STABLE INJECTABLE SOLUTIONS OF FACTOR VIII AND FACTOR IX
DE4111393A1 (en) 1991-04-09 1992-10-15 Behringwerke Ag STABILIZED FACTOR VIII PREPARATIONS
DE69333928T2 (en) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles IMPROVED SOLUBILIZATION AND STABILIZATION OF THE FACTOR VIII COMPLEX
JP3905921B2 (en) 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー COMPOSITION CONTAINING COAGULATION FACTOR VIII, METHOD FOR PRODUCING THE SAME, AND METHOD FOR USING SURFACTANT AS STABILIATOR
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (en) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT2130554E (en) 1999-02-22 2012-11-19 Univ Connecticut Albumin-free factor viii formulations
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004298789A1 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
KR100624013B1 (en) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 Pharmaceutical preparation of recombinant factor ? lyophilized without albumin as a stabilizer
US7523304B2 (en) * 2005-11-22 2009-04-21 Ntt Docomo, Inc. Generation of set coverings with free riders, and generation of ordered sets of meeting points, in systems which include, but are not limited to, systems for broadcast encryption and systems for certificate revocation
RS52459B (en) 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. Stabilized composition of glucocerebrosidase
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
BRPI0708832A2 (en) 2006-03-31 2011-06-14 Baxter Int proteinacean construction
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US8133865B2 (en) 2006-12-27 2012-03-13 Nektar Therapeutics von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
JP5323072B2 (en) 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス Purification of Factor VIII using mixed or multimodal resins
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN103497246B (en) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 The Factor VlII molecule puted together
AU2009289212B2 (en) * 2008-09-03 2015-02-12 Octapharma Ag New protecting compositions for recombinantly produced factor VIII
SI2349342T1 (en) 2008-10-17 2018-10-30 Baxalta GmbH Modified blood factors comprising a low degree of water soluble polymer
US20100168018A1 (en) 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
EP2398822B1 (en) 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
ES2427627T3 (en) 2009-04-06 2013-10-31 Novo Nordisk A/S Targeted delivery of Factor VIII proteins to platelets
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
JP5914363B2 (en) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス Factor VIII molecule with reduced VWF binding
CN102812039B (en) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 Conjugated protein
CN105153313A (en) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 Factor viii fusion protein
EP2560686A2 (en) 2010-04-21 2013-02-27 Novo Nordisk A/S Selective modification of proteins
EP2593130A2 (en) 2010-07-15 2013-05-22 Novo Nordisk A/S Stabilized factor viii variants
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
KR20140084208A (en) * 2011-10-18 2014-07-04 시에스엘 리미티드 Method for improving the stability of purified factor viii after reconstitution
CN102580062B (en) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 Human blood coagulation factor VII I and the dry heat treatment stabilizer of vWF complex or human blood coagulation factor VII I preparation
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2882457A1 (en) * 2012-08-13 2015-06-17 Novo Nordisk A/S Liquid factor viii formulations

Also Published As

Publication number Publication date
RU2689338C2 (en) 2019-05-27
AU2015299224A1 (en) 2017-03-23
KR20170040327A (en) 2017-04-12
CN106687126B (en) 2020-07-28
KR102192494B1 (en) 2020-12-18
IL250343B (en) 2020-10-29
RU2017106159A3 (en) 2018-11-28
BR112017002090B1 (en) 2021-06-01
MX2017000862A (en) 2017-05-01
WO2016020210A8 (en) 2016-04-28
US10238718B2 (en) 2019-03-26
AU2015299224B2 (en) 2019-06-20
CN106687126A (en) 2017-05-17
JP2017528440A (en) 2017-09-28
NZ729629A (en) 2021-12-24
ES2788870T3 (en) 2020-10-23
PL3177317T3 (en) 2020-07-27
JP6516829B2 (en) 2019-05-22
US20170252412A1 (en) 2017-09-07
CA2956412A1 (en) 2016-02-11
WO2016020210A1 (en) 2016-02-11
EP3177317B1 (en) 2020-03-18
BR112017002090A2 (en) 2018-01-30
RU2017106159A (en) 2018-09-06
SG11201700550YA (en) 2017-02-27
EP3177317A1 (en) 2017-06-14
DK3177317T3 (en) 2020-06-15
IL250343A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
ZA201701286B (en) Flagellin compositions and uses
GEP20217239B (en) Pharmaceutical composition
EP3166574A4 (en) Cosmetic compositions
MX2017016405A (en) Nrf2 regulators.
EP3209142A4 (en) Lysolecithin compositions and their use
GB201409348D0 (en) Perfume compositions
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
IL250568A0 (en) Anti-methanogenic compositions and uses thereof
SG10201900598TA (en) Factor viii formulation
MX2016009590A (en) Apilimod compositions and methods for using same.
EP3185888A4 (en) Extracellular matrix compositions
MX2017008390A (en) Alkoxysilane-functionalized and allophanate-functionalized urethanes.
GEP20217240B (en) Pharmaceutical composition
EP3221420A4 (en) Photochromic-electrochromic compositions
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
EP3397252A4 (en) Personal care compositions
EP3107983A4 (en) Fuel compositions
HK1231426A1 (en) Skin-brightening cosmetic composition
SI3220893T1 (en) Composition based on coq10
EP3203995A4 (en) Compositions and methods for the delivery of therapeutics
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
ZA201707872B (en) Compositions comprising anakinra
IL251345A0 (en) Compositions for use in the treatment of peri-implantitis
EP3226882A4 (en) Therapeutic compositions
MY167350A (en) Fat-and-oil composition and chocolate